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Abstract
Introduction Depression is characterized by behavioral, cognitive and physiological changes, imposing a major burden on the
overall wellbeing of the patient. Some evidence indicates that social stress, changes in growth factors (e.g., brain-derived
neurotrophic factor (BDNF)), and neuroinflammation are involved in the development and progression of the disease. The
monoamine oxidase A inhibitor drug harmine was suggested to have both antidepressant and anti-inflammatory properties
and may, therefore, be a potential candidate for treatment of depression.
Aim The goal of this study was to assess the effects of harmine on behavior, brain BDNF levels, and microglia activation in
control rats and a rat model of social stress.
Material and methods Rats were submitted to 5 consecutive days of repeated social defeat (RSD) or control conditions.
Animals were treated daily with harmine (15 mg/kg) or vehicle from day 3 until the end of the experiment. To assess the
effects of harmine treatment on behavior, the sucrose preference test (SPT) was performed on days 1, 6, and 15, the open
field test (OFT) on days 6 and 14, and the novel object recognition test (NOR) on day 16. Brain microgliosis was
assessed using [11C]PBR-28 PET on day 17. Animals were terminated on day 17, and BDNF protein concentrations in
the hippocampus and frontal cortex were analyzed using ELISA.
Results RSD significantly decreased bodyweight and increased anxiety and anhedonia-related parameters in the OFTand SPTon
day 6, but these behavioral effects were not observed anymore on day 14/15. Harmine treatment caused a significant reduction in
bodyweight gain in both groups, induced anhedonia in the SPT on day 6, and significantly reduced the mobility and exploratory
behavior of the animals in the OFT mainly on day 14. PET imaging and the NOR test did not show any significant effects on
microglia activation and memory, respectively. BDNF protein concentrations in the hippocampus and frontal cortex were not
significantly affected by either RSD or harmine treatment.
Discussion Harmine was not able to reverse the acute effects of RSD on anxiety and anhedonia and even aggravated the
effect of RSD on bodyweight loss. Moreover, harmine treatment caused unexpected side effects on general locomotion,
both in RSD and control animals, but did not influence glial activation status and BDNF concentrations in the brain. In
this model, RSD-induced stress was not strong enough to induce long-term effects on the behavior, neuroinflammation,
or BDNF protein concentration. Thus, the efficacy of harmine treatment on these delayed parameters needs to be further
evaluated in more severe models of chronic stress.
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Major depressive disorder (MDD) is a psychiatric disease that
affects the daily life of millions of people and poses a burden to
healthcare systems worldwide (Whiteford et al. 2013).
Depression is mainly characterized by the loss of willingness
to perform activities, sleeping and eating problems, sadness,
and social isolation. Clinical and preclinical research indicates
that decreased neurotransmitter and growth factor activation,
microgliosis, and astrocytosis are involved in the pathogenesis
of depression (Yirmiya et al. 2015; McKlveen et al. 2016; Kim
and Na 2016). Neuroinflammation was suggested to play a
major role in stress response to internal and external challenges,
and increased inflammatory markers have been reported in
MDD patients (Setiawan et al. 2015; Furtado and Katzman
2015), leading to the hypothesis of neuroinflammation-
derived depression. Although the mechanisms are not
completely understood, it is possible that brain inflammation
may be caused by severe or prolonged stressful events and in
turn cause some of the symptoms associated with MDD.
At the same time, drugs that bind to new targets are needed,
and new therapeutic agents that bind to already clinically
established targets are also needed, especially those that can
act in more than one way or control more than one symptom.
Monoamine oxidase-B (MAO-B) inhibitors have been used as
treatment for MDD and other mood disorders for a long time.
However, monoamine oxidase-A (MAO-A) inhibitors may
also be used for this purpose, as the pathways of both enzymes
are intimately related in the metabolism ofmonoamines. In the
brain, the main function of MAO-A is the degradation of
neurotransmitters, such as serotonin (5-HT), dopamine and
norepinephrine, and blocking their release into the synaptic
cleft (Youdim et al. 2006; Jiang et al. 2019). Like many other
interventions used for depression, however, there is a large
variability of treatment efficacy of MAO-A inhibitors, with a
large percentage of MDD patients showing partial or no re-
mission of symptomatology (Sinyor et al. 2010). Harmine is a
β-carboline alkaloid derived from B. caapi (Malpighiaceae)
found mainly in the Amazon rainforest of South America. Its
main mechanism of action is through reversible inhibition of
MAO-A (Iurlo et al. 2002). Harmine is metabolized in the
liver into harmol and hydroxylated harmine and excreted both
via the intestines and the kidneys (Zetler et al. 1974; Jiang
et al. 2015; Zhao et al. 2012). Harmine may be an interesting
candidate drug as it shows not only antidepressant (Fortunato
et al. 2009; Réus et al. 2010b; Liu et al. 2017a) but also anti-
inflammatory properties (Liu et al. 2017b; Li et al. 2018).
Although harmine can be an interesting candidate for
the treatment of depression and anxiety, its effects on the
organism are not yet clear; thus, turning this compound
into a prospective anti-depressant still requires a signifi-
cant amount of steps. The goal of this study is to assess
the short-term and delayed effects of a daily dose of
harmine on behavior of normal rats and rats submitted
to a protocol of psychosocial stress, i.e., repeated social
defeat (RSD). RSD is considered a model of MDD for its
ability to emulate psychosocial stressors of human depres-
sion in an animal model by using territoriality and hierar-
chical status as motivators. The effects of harmine treat-
ment on anhedonia, explorative behavior, anxiety, and
memory were measured with the sucrose preference test
(SPT), the open field test (OFT), and the novel object
recognition test (NOR), respectively. [11C]PBR28 PET of
the brain was performed to assess the delayed effect of
harmine on stress-induced neuroinflammation in various
brain regions. In addition, frontal cortex and hippocampus
were collected after termination for BDNF protein con-
centration analysis. BDNF is a protein associated with
neuronal integrity and neuroprotection.
Material and methods
Animals and drug
The study protocol complied to European Directive
2010/63/EU and the Law on Animal Experiments of
The Netherlands; i t was approved by the Central
Committee on Animal Experiments of The Netherlands
(The Hague, license no. AVD1050020171706) and the
Institutional Animal Care and Use Committee of the
University of Groningen (IvD 171,706–01-006). Male
Wistar rats (HsdCpb:WU, 8 weeks old – Envigo,
The Netherlands) were housed individually at the Central
Animal Facility of the University Medical Center
Groningen. Prior to the experiments, animals were habitu-
ated to the facility for at least 7 days. Animals were main-
tained in rooms with controlled temperature (21 ± 2 °C) and
humidity in a 12/12 h light/dark cycle (lights off at 08:00
P.M.), with food and water provided ad libitum. After accli-
matization, animals were randomly divided into 4 groups (8
animals per group) according to harmine treatment (harmine
or vehicle) and social defeat protocol (RSD or control).
Harmine hydrochloride (Santa Cruz biotechnology; sc-
295136B) was diluted in saline to the desired concentration
of 15 mg/kg in a volume of 1 ml. The solution was then
heated up to 50 °C and stirred with ultrasound until it be-
came a clear solution (about 10 min). When injected in the
animals, the solution was at room temperature.
Study design
A summary of the experiment is presented in Fig. 1. Five days
before the beginning of RSD, the animals were daily trained
for the SPT for 1 h (SPT – training). The first SPT (day 0) was
performed during the night before the first day of RSD.
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Animals were then submitted to the RSD protocol daily for
5 days. The second SPTand the first OFTwere performed one
day after the last RSD trial (day 6). On the third day of RSD,
harmine or vehicle administration was started, which lasted
until the end of the experimental phase (day 3–17). Nine days
after RSD (day 14), animals were submitted to the second
OFT. On day 15, the third SPT test and the training for the
NOR test were performed. On day 16, the NOR test was done.
On day 17, a [11C]PBR28 PET scan was acquired before ter-
mination of the animals and collection of brain tissue for fur-
ther analysis. Animals were weighed daily from day 1 to 17,
always before drug administration.
Drug administration
From day 3 to 17, defeated and control rats were submitted to
a daily intraperitoneal injection of either harmine (15 mg/kg)
or vehicle solution. Harmine caused slight tremors 1 min after
injection, as was previously described in the literature (Cox
and Potkonjak 1971). In our study, the effect lasted for 45–
60 min, and the behavior of the animals returned to normal
after this period. To avoid acute effects of harmine on the RSD
protocol or behavioral parameters, RSD and behavioral as-
sessment were performed in the morning (09:00–12:00
A.M.), while harmine administration was performed in the
afternoon (13:00–14:00 P.M.).
Repeated social defeat
Before the social defeat protocol, 12-weeks old male Long-
Evans rats (residents, HsdBlu:LE, Harlan, The Netherlands;
n = 6; weight, 450–500 g at the beginning of RSD protocol)
were housed with females of the same age in a large wooden
cage (80 × 50 × 40 cm) with a plastic lid. This setup allowed
the resident to develop territorial behavior over a large area.
The Long-Evans rats were submitted to a training social defeat
protocol to allow for the selection of their aggressiveness prior
to the beginning of the first RSD protocol. Animals that
showed an attack latency (i.e., time to initiate the first attack)
of 60 s or less and no signs of violent behavior (i.e., attack
latency of less than 3 s without threatening behavior before the
first attack) during the 5 days of training were selected for the
study. Long-Evans rats that showed non-aggressive or over-
aggressive behavior were excluded from the study.
One hour before the beginning of RSD, the female rat was
removed from the resident’s cage. Then an experimental ani-
mal (intruder, Wistar rat) was placed in the resident’s cage to
begin the defeat protocol. Attack latency and submission time
(i.e., time the intruder takes to show a submissive posture for
at least 3 s) were measured. After the intruder displayed a
submissive posture, it was placed in a wire mesh cage (40 ×
20 × 20 cm) inside the resident’s cage for 60 min. By placing
the intruder in a wire mesh, there is no physical contact be-
tween intruder and resident anymore, but the intruder is still
aware of the presence of the aggressive resident. After 60 min,
the intruder is removed from the resident’s cage and placed
back to its home cage, and the female is placed back in the
resident’s cage. Control animals were placed in a large, plastic
cage for 10 min without resident and subsequently put in the
wire mesh cage for 60 min. Then the animals were placed
back to their home cages. This protocol was repeated on five
consecutive days, and the intruder was always introduced to a
different resident.
Open field test (OFT)
OFT were performed on day 6 and 14 to observe the acute
and delayed effects of harmine treatment in control and
RSD animals. To avoid habituation effects, two different
arenas were used for the trials. For the first OFT, a round
wooden arena of 80-cm diameter was used, whereas a
square arena of 50 × 50 cm2 was used for the second trial.
For both tests, the animal was placed in the room 1 h
before the experiment and left alone during this period.
After 1 h, the investigator placed the animal in the arena
facing the wall and started recording its exploratory be-
havior for 6 min, after which the animal was placed back
into its home cage. The arena was cleaned with ethanol
Fig. 1 Design of the study.
Abbreviations: SPT, sucrose
preference test; RSD, repeated
social defeat; OF, open field test;
NOR, novel object recognition
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70% and dried with paper tissues after each test. Analysis
of the total distance and the time the animal moved, its
velocity, and the time spent in the center and in the pe-
riphery of the arena was performed using Ethovision XT
14.0 software (Noldus, The Netherlands). The number of
times the animal explored the environment (rearing), the
number of times the animal spent grooming, and the time
the animal spent immobile (freezing) were measured man-
ually by the investigator.
Novel object recognition test (NOR)
The NOR test was performed in the circular OFT arena.
The test was performed on day 15 (training) and 16 (long-
term memory). For training, two identical objects (A and
A’ – plastic cylinders) were placed 20 cm from the wall and
20 cm from the center on opposite sides of the field. Thus,
the animal had plenty of space to explore the environment
and interact with the objects separately. For training, the
animals were placed in the arena and allowed to explore
the objects. When the animal had explored each object for
30 s, the training protocol was ended, and the animal was
returned to its cage. If the animal did not reach the explo-
ration criteria after 8 min, the training protocol was also
ended, and the animal was returned to its cage.
For the long-term memory test, the animals are placed
back into the arena 24 h after training, but with one object
being replaced by an object with a different shape and
color (A’ replaced by B – piled Lego bricks). The animal
was placed near the wall of the arena facing the objects
and left to explore freely. During the whole test, the ani-
mal was recorded. After 6 min, the animal was retrieved
and placed back in its home cage. After each trial, the
objects and apparatus are cleaned with 70% ethanol and
dried with paper tissues. Analysis of the time spent ex-
ploring objects A and B were analyzed automatically with
Ethovision XT 14.0. The recognition index (RI) was de-
fined as the time spent exploring object B divided by the
total amount of time exploring both A and B. Animals
that explored the objects for less than 5 s were excluded
from data analysis.
Sucrose preference test (SPT)
Animals were habituated to the SPT protocol by replacing
their water bottle for a bottle containing 1% sucrose for 1 h
on 4 consecutive days. For the test SPT, 2 identical bottles –
one containing drinking water and the other containing 1%
sucrose solution – were placed in the cage of the rat and left
overnight (placement of bottles at 03:00–04:00 P.M.). The
next day, the bottles were removed (at 10:00 A.M.) and
weighed to estimate the amount of fluid consumed by the
animal. The percentage of sucrose intake was calculated from
the weight difference of the 1% sucrose bottle divided by the
sum of the weight differences of both bottles.
Positron emission tomography (PET)
[11C]PBR28 PET was performed on small animal PET scan-
ner (Focus 220, Siemens Medical Solutions, USA) with con-
stant monitoring of the animal’s heart rate and blood oxygen
levels. Anesthesia was induced with 5% isoflurane and main-
tained with 2% isoflurane. After anesthesia induction, a can-
nula was inserted in the lateral tail vein for tracer injection.
[11C]PBR28 (49.6 ± 3.3MBq) was injected as a bolus, and the
animal was placed in its home cage for 30 min. Then the
animal was anesthetized again and a transmission scan with
a Co-57 source was performed for the correction of attenua-
tion and scatter. A 30-min emission scan was started 45 min
after tracer injection.
Images were iteratively reconstructed (OSEM2D, 4 itera-
tions and 16 subsets) after correction for attenuation and ra-
dioactive decay. The reconstructed PET images were automat-
ically co-registered to a [11C]PBR28 rat brain template using
PMOD software (PMOD Technologies LLC, Switzerland).
Regions of interest (ROIs) were delineated for the following
regions: amygdala, cerebellum, corpus callosum, midbrain,
frontal cortex, temporal cortex, dorsal cortex, hippocampus,
hypothalamus, brainstem, olfactory nucleus, thalamus, and
striatum. The average uptake in the ROI’s (in kBq/cc) was
corrected for the injected tracer dose and the bodyweight of
the animals and expressed as standardized uptake value
(SUV).
BDNF analysis
After the PET scan, the animals were transcardially perfused
with cold phosphate-buffered saline pH 7.4 (PBS), and the
brain was removed for tissue analysis. The frontal cortex
and hippocampus were excised from the brain, placed in an
ice-cold PBS solution, snap-frozen in liquid nitrogen, and
stored at − 80 °C until further analysis. RIPA buffer (Sigma-
Aldrich, R0278 – containing 150 mM NaCl, 1.0% IGEPAL®
CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mMTris,
pH 8.0) was added to the brain tissue (50-μl/mg tissue) and
cooled on ice. The tissue was pounded until no solid frag-
ments were visible anymore. The homogenized tissue was
centrifuged at 12,000 rpm for 15 min. The supernatant was
collected for total protein quantification by the bicinchoninic
acid assay (BCA) using bovine serum albumin as a standard.
Then, BDNF was measured with ELISA (Cloud-clone,
SEA011Ra) according to the manufacturer instructions.
Intra-assay precision was < 10%. Tissue lysate was diluted
1:5 in PBS (five samples were diluted 1:6 due to low amount
of lysate). Samples were read at 450 nm and corrected for the
total amount of protein.
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Statistical analysis
Statistical analyses were performed using the two-way gener-
alized linear model (GLM) with RSD and harmine treatment
as factors. Awithin-subject factor (time) was added to the SPT
analysis. The main effects of RSD and harmine were evaluat-
ed, as well as the interaction between both factors and time,
whenever needed. For all tests, p < 0.05 was considered sta-
tistically significant. SPSS 23 (IBM, United States) was used
for all statistical analyses.
Results
Social defeat and harmine treatment decrease
bodyweight gain
Figure 2 depicts the effect of RSD and harmine on
bodyweight gain over time. As expected, there was a sig-
nificant effect of time on bodyweight within animals (F =
11.380, p < 0.001). Additionally, there was a significant
effect of RSD and harmine treatment on bodyweight gain
(RSD, F = 3.275; p = 0.040; Harmine, F = 0.192;
p < 0.001), but no interaction between RSD and harmine
treatment (p > 0.05). RSD induced a significant reduction
in bodyweight gain compared to the control groups
(F(1,25) = 12.123, p = 0.002), and also, harmine treatment
caused a significant reduction in bodyweight gain when
compared to vehicle treated controls (F(1.25) = 28.624,
p < 0.001) Figure 3.
Harmine treatment seemed to have a stronger effect on
bodyweight than RSD, as harmine-treated animals
showed a significant difference when compared to
vehicle-treated animals until the end of the experiment
(day 17 – p < 0.05 at all time points), with no return to
normal levels when compared with vehicle animals. The
significant reduction in bodyweight induced by RSD
lasted only until day 12 (p < 0.05), after which the effect
of RSD was normalized.
Acute, but no long-term effect of harmine and RSD
on sucrose intake
Sucrose preference test was performed on days 1, 6, and
15. There was a main effect of time (F(2,54) = 17.270,
p < 0.001) and a main effect of RSD (F = 3.797, p =
0.036) on SPT, but no main effect of harmine treatment
or any interaction. Further pairwise comparisons showed a
significant decrease in sucrose intake due to RSD on day
6, when compared with the other time points (RSD day 6
vs RSD days 1 and 15, p < 0.001), while such a temporal
effect was not observed in controls.
Interestingly, pairwise comparisons within vehicle and
harmine groups showed similar results as those found in
control and RSD groups, with sucrose intake by harmine-
treated animals being significantly lower on day 6 than on
the other days (harmine day 6 vs harmine days 1 and 15,
p < 0.001), but no difference between time points was ob-
served in the vehicle groups.
Transient effect of RSD on anxiety-like behavior
The effect of RSD and harmine treatment on anxiety was
assessed by the time the animal spent in the center of the arena
during the OFT. As expected, animals that underwent RSD
spent significantly less time in the center of the arena on day 6
(F = 4.747, p = 0.038 – Fig. 4). However, no difference be-
tween animals injected with harmine and vehicle was found.
There were no significant interactions between RSD and
harmine treatment, suggesting that harmine was unable to re-
verse the effects of RSD. On day 14, animals submitted to an
RSD protocol did not show any anxiety-like behavior any-
more, as shown by the lack of significance between RSD
and controls. Treatment with harmine had no long-term effect
on the anxiety-like behavior either(all p > 0.05).
Effect of harmine on mobility
Harmine treatment significantly reduced the time the animal
spent moving in the OFT on day 6 (F = 6.356, p = 0.018) and
Fig. 2 Bodyweight change over
time. a p < 0.05 between harmine
and vehicle treatment for each
time point until day 17. b p < 0.05
between RSD and control for
each time point until day 12.
Points and whiskers represent
mean ± SEM
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day 14 (F = 7.283, p = 0.012 – Fig. 5). Likewise, the total
distance moved by harmine-treated animals was significantly
smaller than the distance traveled by vehicle-treated animals
(F = 7.283, p = 0.012). RSD did not have any effect on mobil-
ity neither on day 6 nor on day 14.
Additionally, there was a significant effect of harmine
treatment on rearing (exploratory behavior). Animals ad-
ministered with harmine display less frequently a rearing
posture (F = 4.475, p = 0.012). RSD did not have any ef-
fect on rearing frequency (Fig. 4).
No effect of harmine treatment on long-termmemory
The NOR test did not show any effect of harmine or RSD on
long-termmemory, as no significant differences in recognition
index between groups were observed (p > 0.05) (Fig. 6).
Fig. 4 Effect of social defeat on the time spent in the inner zone of the arena (a–b) and number of rearings (c–d) in the OFTon day 6 (left panel) and day
14 (right panel). Horizontal lines and whiskers indicate median ± 95% CI, respectively; sample size, 7–8 animals per group
Fig. 3 Sucrose preference on day
1, 5, and 14 showing the effects of
RSD and harmine treatment. The
horizontal line and whiskers
represent median ± 95% CI,
respectively. A main effect of
time was observed (p < 0.001). In
addition, a significant effect of
RSD on sucrose preference was
found on day 5 (p < 0.05)
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No effect of harmine treatment on glial activation
For all groups, [11C]PBR28 PET showed highest tracer up-
take in the olfactory nucleus, frontal and dorsal cortex, and
cerebellum. However, stress-induced glial activation could
not be detected on day 17, as there was no significant effect
of RSD on the uptake (SUV) of [11C]PBR28 in any of the
brain regions assessed (all p > 0.05 – Fig. 7). Harmine did
not have any effect on the glial activation status either, as
[11C]PBR28 PET did not show any significant differences,
neither in the control group nor in the RSD group.
No chronic effect of harmine treatment on BDNF
concentration
There was no significant main effect of treatment with
harmine or RSD on the BDNF concentration in the hip-
pocampus or frontal cortex (p > 0.05 – Fig. 8). As
BDNF is highly correlated with cognitive parameters,
we also assessed if there was a significant relationship
between memory and the concentration of BDNF in ei-
ther brain region using linear regression, but did not find
any correlation.
Fig. 5 Acute (left panel) and long-term (right panel) effect of harmine treatment on the distance traveled (a–b) and time spent on movement (c–d).
Horizontal lines and whiskers indicate median ± 95% CI, respectively; sample size, 7–8 animals per group
Fig. 6 Results of the NOR test on
day 16, showing no effect of RSD
or harmine treatment on long-
term memory. Horizontal lines
and whiskers indicate median ±
95% CI, respectively; sample
size, 6–7 animals per group
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Discussion
This study aimed to assess the effect of harmine on behavior,
glial activation, and BDNF concentrations, both in healthy
rats and rats submitted to an RSD protocol. Harmine proved
unable to reverse the acute anxiety and anhedonia induced by
the RSD protocol. However, harmine had a negative long-
term effect on the bodyweight gain, especially in rats exposed
to a stressful situation. Additionally, harmine had a significant
effect on the general locomotion, both on day 6 (3 days after
first injection) and on day 14 (11 days after first injection), but
did not affect long-term memory, glial activation status, or
BDNF concentrations on day 16/17.
Harmine is unable to reverse RSD -induced anxiety
and depressive-like behavior
Animals submitted to RSD showed more anxiety (time spent
in the center of the open field arena) and depressive-like
behavior (preference of sucrose solution over water) than con-
trols. These results are supported by literature showing that
several stressors can induce anxiety and depression-associated
parameters in animals (Riga et al. 2015; Liu et al. 2017a, c)
(Miczek et al. 2008; Wohleb et al. 2014). Although our results
show an acute increase of anxiety and depression-associated
measures in animals submitted to RSD, this effect did not last
until 9 days after RSD. This transient effect has previously
been observed in various RSD protocols, using different spe-
cies, number of defeats, RSD duration, and evaluation period.
Kopschina Feltes and colleagues observed in Wistar rats that
the effect of a similar RSD protocol was observed 1 week after
RSD but was resolved after 90 days (Kopschina Feltes et al.
2019). Martin and colleagues used a modified 10-day RSD
protocol on C57BL mice and found that the transient effect of
RSD had normalized after 18 days (Martin et al. 2017).
Gottschalk et al. found that a 5-day RSD protocol has a sig-
nificant effect on anhedonia 3 days after the last RSD expo-
sure (Gottschalk et al. 2018). We also reported a significant
Fig. 7 Results of [11C]PBR28
PET, showing no significant
effect of RSD or harmine
treatment on tracer uptake (SUV)
in any brain region of interest.
Bars and error bars represent
mean and SEM, respectively;
sample size, 7–8 animals per
group
Fig. 8 BDNF concentration in hippocampus and frontal cortex on day
17, showing no significant effects of RSD or harmine treatment. BDNF
concentrations are corrected for the total concentration of protein.
Horizontal lines and error bars represent mean ± 95% CI, respectively;
sample size, 5–8 samples per group
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effect of RSD on anhedonic behavior, although the SPT
showed a large variability 1 day after RSD. We hypothe-
size that this variance can be the effect of the resilience/
proneness of the animals toward stress. Krishnan and col-
leagues also found a strong variance in a large cohort of
mice submitted to social defeat stress, with a remarkable
difference between resilient and prone animals toward
stress (Krishnan et al. 2007). Febbraro and colleagues
recently showed a similar difference in response in rats
after chronic mild stress (Febbraro et al. 2017).
Both MAO-A and MAO-B inhibitors have historically
been used as an antidepressant agent with variable effec-
tiveness. Inhibition of either MOA subtype leads to re-
duced monoamine degradation and consequently increased
monoamine levels in the synaptic cleft (Youdim et al.
2006; Finberg and Rabey 2016). Our study shows that
acute administration of MAO-A inhibitor harmine was un-
able to improve the acute depressive-like state of the ani-
mals subjected to RSD. Although there are no studies on
the acute therapeutic effect of harmine after social stress, it
is known that mid- to long-term administration of harmine
improves depressive-like symptomatology in animals sub-
mitted to a chronic unpredictable stress protocol (Abelaira
et al. 2013). One study reported that chronic administration
of harmine prior to application of chronic unpredictable
stress was able to mitigate the stress-induced depressive-
like behavior (Liu et al. 2017a). Another study investigated
the therapeutic effect of chronic harmine administration for
1 week in chronically stressed rats and found similar re-
sults, using the preference for sugary food the main out-
come measure (Fortunato et al. 2010). These studies, how-
ever, were performed in a chronic mild stress model (CMS)
and therefore are difficult to translate to the stress protocol
used in our study. When compared with CMS, RSD can be
considered a more ecologically viable option for a stressor,
as it uses the normal rodent behavior to present a stressful
situation (i.e., fight-or-flight), thus improving its construct
validity to what is observed in human stress studies. The
lack of acute effect of harmine can be explained by its
mechanism of action. In humans, MAO inhibitors are
known to take two or more weeks for mitigation of depres-
sive symptoms to occur. Therefore, short bouts of MAO
inhibitors likely have no effect on symptomatology of de-
pression. Another significant methodological difference
between previous studies and our findings is the timing
of drug administration. Other studies that assessed animal
behavior did so 60 min after injection of the drug (Abelaira
et al. 2013). It is plausible that the observations in previous
studies were more related to acute (i.e., drug injection)
rather than chronic effects of harmine administration. Our
goal was to investigate the effect of chronic harmine treat-
ment on the behavioral tasks and therefore we performed
the behavioral tests before injection of the drug.
Harmine and RSD cause bodyweight loss
Both RSD and harmine treatment caused a reduction in
bodyweight. The effect of RSD is in line with previous liter-
ature describing that animals submitted to the RSD show tran-
sient weight loss – or a lower weight gain – during the period
of such protocol (Becker et al. 2008; Kopschina Feltes et al.
2019). Stress can increase brown adipose tissue thermogene-
sis and hyperthermia and thus cause a reduction in
bodyweight (Zhang and Bi 2015). The effect of harmine treat-
ment on bodyweight might be due to a similar mechanism, as
harmine is able to induce adipose tissue thermogenesis by
blocking Ucp1 gene inhibition by chromodomain helicase
DNA binding protein 4 (CHD4) (Nie et al. 2016).
Interestingly, the effect of harmine on bodyweight seemed to
be exacerbated after exposure to a stressor, suggesting an in-
teraction between harmine and stress mechanisms. One report
has shown that the effect of harmine on adipocyte thermogen-
esis is related to activation of the ERK, p38, and AKT path-
ways (Nie et al. 2016). In the brain, these pathways are also
involved in the modulation of several neuronal functions that
may affect the stress response.
Harmine reduces locomotion
Our findings show that harmine significantly decreased the
general movement of the animals, as measured by their im-
mobility time on day 6 and 14. Unlike our study, others have
not observed any differences in locomotion after acute or
chronic administration of harmine for 12 days (Fortunato
et al. 2009; Réus et al. 2010a). However, another study
showed that the harmine analogs, harmane, and norharmane
induced a significant decrease in the distance traveled by the
animals, but no differences in anxiety or motor coordination
outcomes (Goodwin et al. 2015). Harmine has been suggested
as a potential metabolite of harmane (Guan et al. 2001) and
thus this metabolite, rather than harmane itself, could be re-
sponsible for the observed effect on locomotion. However, a
recent study disputes harmine being a metabolite of harmane
(Li et al. 2016), which would undermine this hypothesis.
Previous research has shown that acute administration of
harmine causes tremorgenic effects on rats (Cox and
Potkonjak 1971). In this study, we also found that harmine
administration caused transient tremors, which lasted for ap-
proximately 60 min (data not shown). Although the tremors
were not visible anymore after 1 h, it may have had some
lingering effect on the general locomotion. Indeed, one of
the main side effects of monoamine oxidase inhibitors is
movement impairment due to increased serotonin neurotrans-
mission (i.e., serotonin syndrome) (Brierley and Davidson
2012). Likewise, one could speculate that the reduced mobil-
ity induced by the administration of harmine in our study
could be the cumulative effect of the daily treatment on
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serotonin neurotransmission. However, further investigation
of the mechanisms for the effect of harmine on general loco-
motion is needed.
RSD and harmine do not affect long-term memory,
BDNF levels, or glial activation
In our study, RSD by itself was unable to induce long-term
memory changes. This is similar to what was found previ-
ously in our laboratory (Kopschina Feltes et al. 2019).
Other studies, however, showed that different subtypes of
memory are affected by RSD. McKim and colleagues
found that a 6 days RSD protocol was able to impair spatial
memory recall, as assessed with the Morris and Barnes
mazes (McKim et al. 2016). Wohleb and colleagues found
that this effect lasts for up to 8 days, suggesting a sub-
chronic effect of RSD (Wohleb et al. 2014). It is worth
noting that memory tests can pose stressful environments
and the NOR test is considered a substantially less stressful
event than the Barnes maze or Morris water maze; compar-
ison between the tests is therefore difficult.
A recent meta-analysis suggested that harmine is able to
reverse stress-related memory impairment (dos Santos and
Hallak 2017). However, this effect was not observed in our
study, with both harmine and vehicle-treated animals
showing similar memory performance whether a stressor
was present or not. A similar study using chronic unpre-
dictable stress (CUS) for 40 days also did not show any
significant effect of harmine on memory (Abelaira et al.
2013). In our study, the effect of the stressor seemed to
be transient, and on the day of the memory test, the effect
of the social stressor already had resolved. Further studies
are needed with stressors that are able to induce long-term
cognitive impairment to assess the effect of harmine ad-
ministration on stress-induced cognitive impairment.
Reduced levels of BDNF protein in specific regions of the
brain has been associated with cognitive impairment (Knable
et al. 2004; Saruta et al. 2010; Autry and Monteggia 2012;
Reinhart et al. 2015; Chen et al. 2017). Treatment of brain
disorders is generally accompanied by an alteration – usually
an increase – in BDNF levels (Coppell et al. 2003; Lee and
Kim 2008; Cooke et al. 2009). In this study, there was no
effect of RSD or treatment with harmine on BDNF concentra-
tion in the frontal cortex or hippocampus. The absence of an
effect of RSD on BDNF levels might be explained by the
transient effect of the stressor used in this study, resulting in
a normalization of BDNF levels at the time of assessment.
Other studies suggest that assessment at an earlier time point
could have shown changes in BDNF concentration (Hoffman
et al. 2015). However, earlier assessment may potentially have
been too soon to observe any effect of harmine treatment, as
treatment with antidepressant drugs often takes at least 1 week
to induce behavioral changes. Another point to take into
consideration is the high variability in the BDNF concentra-
tion. Since normal variability in BDNF is high, increasing the
sample size will increase the statistical power and may help to
understand the effects of both RSD stress and harmine in
BDNF concentration in future studies.
[11C]PBR28 PET imaging did not show any significant
effect of the social stress protocol or harmine treatment on
glial activation. It is known that microglial activation
starts hours after exposure to the stressor and can last
for several days or even weeks, decreasing gradually as
the resolution of neuroinflammation begins (Schwartz and
Baruch 2014). Kopschina Feltes and colleagues found a
significant effect of the RSD protocol on [11C]PK11195
uptake 6 days after RSD in several key regions associated
with depressive behavior (e.g., medial prefrontal cortex,
entorhinal cortex, and insular cortex), but this effect was
not observed anymore 3 weeks after RSD (Kopschina
Feltes et al. 2019). In our study, apparently either the
neuroinflammatory process was not severe enough to be
shown by PET imaging or the neuroinflammatory re-
sponse had already resolved 11 days after the last RSD
trial. The latter option is in line with the results of the
behavioral studies, which also did not elicit long-term
changes in behavioral parameters associated with
depressive-like behavior. [11C]PBR28 PET also did not
show any significant effect of harmine treatment on tracer
uptake, neither in controls nor in defeated animals. The
latter is most likely due to the lack of an effect of RSD on
glial activation at the time of the PET scan.
Conclusion
Harmine was not able to reverse the RSD-induced acute
anxiety and depressive-like behavior observed in the
OFT and SPT shortly after exposure to the stressor.
However, harmine treatment caused a number of side
effects in control and RSD animals. Harmine treatment
caused significant bodyweight loss, especially in animals
exposed to the stress of the RSD protocol. In addition,
harmine caused acute and delayed changes the locomotor
behavior of animals, irrespective of the stressor. On the
other hand, harmine did not alter the glial activation state
of the brain or BDNF concentration in frontal cortex or
hippocampus, regions that are key for stress regulation
and further brain homeostasis. To better assess the anti-
depressant and anti-inflammatory effects of harmine, fur-
ther studies using different stressors or longer-lasting
RSD protocols to induce a chronic stress response in
the organism are needed. In this context, it might be of
interest to compare the effects of harmine in animals
submitted to either RSD or CMS, as studies with these
models appear to show different results.
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